Health Care • Biotechnology: Pharmaceutical Preparations
$24.80 ▲ +0.53
(+2.18%)
MKT CAP: $2.81B • VOL: 1.91M
52W L $13 52W H $34
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
VRDN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$363.4M | -$299.0M | -$254.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$342.6M | -$269.9M | -$237.7M |
| EBITDA (Normalized) | -$363.0M | -$298.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$276.4M | -$232.3M | -$184.2M |
| Capital Expenditures (CapEx) | $495.0K | $511.0K | — |
| Free Cash Flow (FCF) | -$276.9M | -$232.8M | -$184.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -39.8% | -34.1% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | $20.6M | — |
| Total Stockholders' Equity | $722.2M | $671.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VRDN.